Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aspen Aerogels Inc (ASPN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Aspen Aerogels IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Aspen Aerogels Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Aspen Aerogels Inc trades at $6.14 (market cap $509.55M), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.

ASPNXBI
Market Cap
$509.55M
Sector
TechnologyBroad Market / Factor
52-Week High
$8.82$164.28
52-Week Low
$2.57$86.92
Enterprise Value
$482.96M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aspen Aerogels Inc

ASPN trades at $6.15, down 2.23% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue beat but missed EPS estimates, with a net income margin of -62.45% and negative cash flow. Recent news highlights sequential revenue improvement and a raised European Thermal Barrier outlook for 2026.

Outlook hinges on execution of Q3 revenue guidance of $65-80M and adjusted EBITDA of $7-15M. Risks include persistent losses and competitive pressures, but analyst consensus is strongly bullish with 82.61% buy ratings, suggesting confidence in the recovery trajectory.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI